COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea

Condé, Kaba; Atakla, Hugues Ghislain; Garba, Mahaman Salissou; Garba, I

doi:10.11604/pamj.supp.2020.35.2.24616

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In systemic sclerosis, endothelial injury causes vascular leakage, promoting inflammation in the lungs, heart, and other organs [ 86 ]. Such pre-existing lung fibrosis may deteriorate COVID-19 infection in SSc patients [ 87 ]. There is substantial evidence that the endothelium plays a significant role in the pathogenesis of both SSc and COVID-19 [ 88 ].…”

Section: Rare Autoimmune Diseasesmentioning

confidence: 99%

A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases

Hamidi

Jabraeili-Siahroud

Taati-Alamdari

et al. 2023

Virol J

View full text Add to dashboard Cite

After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a global pandemic. The coronavirus disease 2019 (COVID-19) pandemic, raises concerns for all people, mainly for susceptible population. People with pre-existing diseases, especially individuals with autoimmune disorders, are more at the risk of SARS-CoV-2 infection because of compromised immune system due to frequent use of immunosuppressive drugs and steroids. Patients with autoimmune diseases and their physicians have concerns about these patients’ healthcare, since they are at a higher risk for COVID-19 infection, may show severe complications of COVID-19, and may experience probable flares of their pre-existing disease. Even though there have been several studies discussing the relation between COVID-19 and various types of autoimmune diseases, it cannot be ascertained that all patients with autoimmune diseases experience more severe complications of COVID-19 and have more hospitalization or mortality rate. The situation depends on each patient’s condition, such as the type and the severity of the underlying autoimmune disease and the kind of treatment they receive. In the present review, we have discussed the effects of COVID-19 pandemic on patients with different autoimmune diseases and their relative concerns about their treatments. As a result, we have reviewed further considerations that should be taken into account for these patients during the pandemic or when they are infected with COVID-19.

show abstract

Section: Rare Autoimmune Diseasesmentioning

confidence: 99%

A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases

Hamidi

Jabraeili-Siahroud

Taati-Alamdari

et al. 2023

Virol J

View full text Add to dashboard Cite

show abstract

Methotrexate/prednisolone

2021

Reactions Weekly

View full text Add to dashboard Cite

A case report of two patients described a 52-year-old man, who developed COVID-19 during treatment with methotrexate and prednisolone for rheumatoid arthritis.The man had rheumatoid arthritis since 2012. He had been receiving methotrexate 20 mg/week and prednisolone 10 mg/day [routes not stated] for rheumatoid arthritis. In April 2020, he was admitted to the emergency department in Guinea for a flare-up of his rheumatoid arthritis associated with an influenza-like illness. He had a fever of 38.2°C with difficulty breathing and a cough. He had blood pressure of 130/80mm Hg, heart rate of 111 beats/minute and oxygen saturation of 83%. Physical examination revealed inflammatory synovitis in the wrists, at metacarpophalangeal 2 and 3 and in knees bilaterally. Cardiopulmonary examination revealed tachycardia associated with crackling rales at both lung bases. The remaining of the examination was unremarkable. The biological examination revealed a normal blood count, a non-specific inflammatory syndrome with a sedimentation rate (SV) of 52 mm/hour and a C-reactive protein (CRP) of 35 mg/L. Liver and renal functions were normal. Cytobacteriological examination of the blood and urine culture were negative on two occasions. Chest X-ray revealed a mundane interstitial lung disease. Thoracic CT revealed lesions suggestive of COVID-19 [durations of treatments to reactions onsets not stated].The man was placed in isolation and started receiving standard treatment adopted by Guinea comprising chloroquine 1000 mg/day and azithromycin [Azythromycin] 500 mg/day along with unspecified corticosteroid. Methotrexate was discontinued. He tested positive on the COVID-19 PCR confirmatory test performed on admission. Thus the diagnosis of COVID-19 infection associated with rheumatoid arthritis was retained. He was discharged 33 days later following regression of symptoms and the RTPCR test was negative on two occasions.

show abstract

When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review

Santos

Vieira

Wietholter

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea

Cited by 4 publications

References 10 publications

A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases

A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases

Methotrexate/prednisolone

When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review

Contact Info

Product

Resources

About